CN108697795A - Gfral受体疗法 - Google Patents

Gfral受体疗法 Download PDF

Info

Publication number
CN108697795A
CN108697795A CN201680082844.2A CN201680082844A CN108697795A CN 108697795 A CN108697795 A CN 108697795A CN 201680082844 A CN201680082844 A CN 201680082844A CN 108697795 A CN108697795 A CN 108697795A
Authority
CN
China
Prior art keywords
gfral
leu
compound
receptors
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680082844.2A
Other languages
English (en)
Chinese (zh)
Inventor
吴心乐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN108697795A publication Critical patent/CN108697795A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201680082844.2A 2016-02-29 2016-02-29 Gfral受体疗法 Pending CN108697795A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2016/074809 WO2017147742A1 (en) 2016-02-29 2016-02-29 Gfral receptor therapies

Publications (1)

Publication Number Publication Date
CN108697795A true CN108697795A (zh) 2018-10-23

Family

ID=59742416

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680082844.2A Pending CN108697795A (zh) 2016-02-29 2016-02-29 Gfral受体疗法

Country Status (4)

Country Link
EP (1) EP3423094A4 (https=)
JP (1) JP2019510739A (https=)
CN (1) CN108697795A (https=)
WO (1) WO2017147742A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069636A (zh) * 2016-03-04 2018-12-21 恩格姆生物制药公司 用于调节体重的组合物和方法
WO2023274276A1 (zh) * 2021-06-30 2023-01-05 上海津曼特生物科技有限公司 抗gfral抗体及其应用
CN116444667A (zh) * 2023-06-13 2023-07-18 上海驯鹿生物技术有限公司 一种靶向gdf15的全人源抗体及其应用
WO2024183468A1 (zh) * 2023-03-03 2024-09-12 北京志道生物科技有限公司 一种多肽分子

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2694092B1 (en) 2011-04-08 2017-01-04 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
MY194669A (en) 2016-03-31 2022-12-12 Ngm Biopharmaceuticals Inc Binding Proteins and Methods of use Thereof
KR20190059312A (ko) * 2016-10-12 2019-05-30 얀센 바이오테크 인코포레이티드 Gdf15-유사 생물학적 활성의 조절제에 대한 스크리닝 방법
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
EA202191105A1 (ru) * 2018-10-22 2021-08-03 Янссен Фармацевтика Нв Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение
EP4041281B1 (en) 2019-10-04 2025-11-26 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
KR20220150270A (ko) 2019-10-07 2022-11-10 칼리오페, 인크. Gpr119 효능제
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
US12398211B2 (en) 2020-06-04 2025-08-26 Daegu Gyeongbuk Institute Of Science And Technology GFRAL-antagonistic antibody and use thereof
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
US20240182585A1 (en) 2021-03-31 2024-06-06 Cambridge Enterprise Limited Therapeutic inhibitors of gdf15 signalling
IT202300006387A1 (it) * 2023-03-31 2024-10-01 Univ Degli Studi Roma La Sapienza Inibitore del recettore gfral per uso nel trattamento della sclerosi laterale amiotrofica

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101854947A (zh) * 2007-08-16 2010-10-06 圣文森特医院悉尼有限公司 用于调节巨噬细胞抑制因子(mic-1)活性的药剂和方法
CN102321173A (zh) * 2011-08-12 2012-01-18 中国医学科学院肿瘤研究所 人源化巨噬细胞抑制因子1单克隆抗体及其应用
CN103533951A (zh) * 2011-04-08 2014-01-22 安姆根有限公司 使用生长分化因子15(gdf-15)治疗或改善代谢障碍的方法
CN104768974A (zh) * 2012-08-22 2015-07-08 瑞泽恩制药公司 GFRα3的人抗体及其使用方法
CN105073133A (zh) * 2012-12-21 2015-11-18 Aveo制药公司 抗gdf15抗体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2478369A1 (en) * 2002-03-05 2003-09-18 Genentech, Inc. Novel polypeptides having sequence similarity to gdnfr and nucleic acids encoding the same
WO2017121865A1 (en) * 2016-01-15 2017-07-20 Novo Nordisk A/S Mic-1 receptor and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101854947A (zh) * 2007-08-16 2010-10-06 圣文森特医院悉尼有限公司 用于调节巨噬细胞抑制因子(mic-1)活性的药剂和方法
CN103533951A (zh) * 2011-04-08 2014-01-22 安姆根有限公司 使用生长分化因子15(gdf-15)治疗或改善代谢障碍的方法
CN102321173A (zh) * 2011-08-12 2012-01-18 中国医学科学院肿瘤研究所 人源化巨噬细胞抑制因子1单克隆抗体及其应用
CN104768974A (zh) * 2012-08-22 2015-07-08 瑞泽恩制药公司 GFRα3的人抗体及其使用方法
CN105073133A (zh) * 2012-12-21 2015-11-18 Aveo制药公司 抗gdf15抗体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ZHIHUA LI 等: "Identification, expression and functional characterization of the GRAL gene", 《J NEUROCHEM》 *
刘翾 等: "GDNF家族受体a（GFRa）样蛋白GFRAL在哺乳动物神经细胞的表达和功能研究", 《中国神经科学学会会议论文集》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069636A (zh) * 2016-03-04 2018-12-21 恩格姆生物制药公司 用于调节体重的组合物和方法
WO2023274276A1 (zh) * 2021-06-30 2023-01-05 上海津曼特生物科技有限公司 抗gfral抗体及其应用
WO2024183468A1 (zh) * 2023-03-03 2024-09-12 北京志道生物科技有限公司 一种多肽分子
CN116444667A (zh) * 2023-06-13 2023-07-18 上海驯鹿生物技术有限公司 一种靶向gdf15的全人源抗体及其应用
CN116444667B (zh) * 2023-06-13 2023-09-01 上海驯鹿生物技术有限公司 一种靶向gdf15的全人源抗体及其应用

Also Published As

Publication number Publication date
WO2017147742A1 (en) 2017-09-08
EP3423094A1 (en) 2019-01-09
JP2019510739A (ja) 2019-04-18
EP3423094A4 (en) 2019-11-06

Similar Documents

Publication Publication Date Title
CN108697795A (zh) Gfral受体疗法
JP6783797B2 (ja) 抗がん融合ポリペプチド
ES2646168T3 (es) Anticuerpos monoclonales para el receptor del factor de crecimiento de fibroblastos 2
EP1554309A2 (en) Antibodies and cyclic peptides which bind cea (carcinoembryonic antigen) and their use as cancer therapeutics
RU2702553C2 (ru) Новое антитело против tie-2 человека
TW201932484A (zh) 結合ａｌｋ－１及ｂｍｐｒ－２之雙特異性抗體
CN109988240B (zh) 抗gpc-3抗体及其用途
EA021584B1 (ru) Ингибитор рецептора фактора роста фибробластов-3 (fgfr-3) и его применение
CN113677699B (zh) 神经调节蛋白-4化合物和使用方法
JP2020501506A (ja) 抗ＮＫｐ４６抗体およびその治療的使用
TW201000129A (en) Interleukin-21 receptor binding proteins
CN112105629A (zh) 调节性t细胞表面抗原的表位以及与其特异性结合的抗体
CN111378040B (zh) 检测多种恶性肿瘤细胞的抗体及其应用
EP2828291A1 (en) Peptides derived from the d1-domain of nkp46
CN111378039A (zh) 治疗恶性肿瘤的抗体及其应用
JP2023554351A (ja) 新規の徐放性プロドラッグ
WO2006125632A2 (en) Agonistic antibodies that bind to the tweak receptor fn14 and thereby modulate adiposity-associated phenotypes as well as their use in therapy
WO2022242757A1 (zh) 抗pd-1抗体的应用
KR20220048028A (ko) 항-cd19 항체 및 그의 용도
RU2846293C1 (ru) АНТИТЕЛО К EphA4
EP3145545B1 (en) Bak binding proteins
WO2025252023A1 (en) Modulators for gipr, glp1r and/or gcgr and uses thereof
US20060024314A1 (en) Antibodies and cyclic peptides which bind CEA (carcinoembryonic antigens) and their use as cancer therapeutics
US6872703B2 (en) Insulin receptor-related receptor binding protein
JP2002335972A (ja) インスリン受容体関連受容体結合蛋白質及びその利用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20181023